Clinical

Dataset Information

0

Phase II study of XELIRI with bevacizumab as second-line therapy for metastatic colorectal cancer -Beyond Progression Disease of capecitabine and bebacizumab -


ABSTRACT: Interventions: Bevacizumab (7.5mg/kg) and CPT-11(200mg/m2) is administered on day1, and capecitabine (1600mg/m2) is administered from day 1 to day 14 Primary outcome(s): response rate Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2622299 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2622964 | ecrin-mdr-crc
| 2620502 | ecrin-mdr-crc
| 2623247 | ecrin-mdr-crc
| 2624073 | ecrin-mdr-crc
| 2630432 | ecrin-mdr-crc
| 2621169 | ecrin-mdr-crc
| 2621739 | ecrin-mdr-crc
| 2620819 | ecrin-mdr-crc
| 2638283 | ecrin-mdr-crc
| 2643874 | ecrin-mdr-crc